Brown, Lisle/Cummings’s Takeda Pharmaceutical TAK Stock Holding History

Brown, Lisle/Cummings’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.07K	Hold	58	–	–	﹤0.01%	927
2025 Q4	$904	Hold	58	–	–	﹤0.01%	691
2025 Q3	$849	Hold	58	–	–	﹤0.01%	716
2025 Q2	$897	Hold	58	–	–	﹤0.01%	714
2025 Q1	$862	Buy	+58	New	+$813	﹤0.01%	721

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Brown, Lisle/Cummings's TAK Position: Q1 2026 in Review

Brown, Lisle/Cummings held its Takeda Pharmaceutical (TAK) position steady in Q1 2026 at 58 shares worth $1.07K. The position accounts for ﹤0.01% of the portfolio, ranked #927.

Brown, Lisle/Cummings first reported a position in TAK in Q1 2025 and has held it in 5 quarters since. 361 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

Brown, Lisle/Cummings held 58 shares of Takeda Pharmaceutical worth $1.07K as of Q1 2026.
Brown, Lisle/Cummings left its Takeda Pharmaceutical share count unchanged in Q1 2026.
Takeda Pharmaceutical made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q1 2026, its #927 holding.
Brown, Lisle/Cummings first reported a position in Takeda Pharmaceutical in Q1 2025 and has held it in 5 quarters since.
361 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2026, filed 20 Apr 2026.